# Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

> **NCT03312283** · PHASE1 · COMPLETED · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** lucentis
- **DRUG:** QL1205

## Key facts

- **NCT ID:** NCT03312283
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-20
- **Primary completion:** 2019-04-02
- **Final completion:** 2019-04-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312283, "Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03312283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*